Third Rock Ventures’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Third Rock Ventures’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$622M	Buy	+14,760,900	New	+$696M	58.1%	1

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Third Rock Ventures's GBT Position: Q3 2015 in Review

Third Rock Ventures opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q3 2015: 14,760,900 shares worth $622M. The stake represents 58.1% of the portfolio and ranks #1 among its holdings.

59 funds tracked by Wall St. Rank hold GBT as of Q3 2015.

Third Rock Ventures held 14,760,900 shares of Global Blood Therapeutics, Inc. worth $622M as of Q3 2015.
Global Blood Therapeutics, Inc. was a new Third Rock Ventures position in Q3 2015.
Global Blood Therapeutics, Inc. made up 58.1% of Third Rock Ventures's portfolio in Q3 2015, its #1 holding.
59 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2015.

Based on Third Rock Ventures's 13F filing for Q3 2015, filed 3 Nov 2015.